ClinicalTrials.gg
CompletedNCT00772967Updated Nov 20, 2015Results posted

A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)

A Phase 1 interventional study of Naproxen and Placebo in Osteoarthritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2015-11-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies testing naproxen in Osteoarthritis — none open to participants now, 1 under way, none of them phase 3. Naproxen · Osteoarthritis.

Enrollment
13th of 14
22 · median 103
Started
2008
with 3 others
Phase 1
5 of 14
none open now
Registered
8th of 14
by date
Lead sponsor
1 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing naproxen in Osteoarthritis, this one is the 13th largest by enrollment, is one of 4 that started in 2008, is one of 5 in phase 1, and was the 8th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing naproxen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing naproxen in Osteoarthritis as a file.
02

Study summary

This study will evaluate a walking model of osteoarthritis for use in testing of new therapeutic agents. The primary hypothesis is that participants treated with Naproxen or Ultracet will have lower Pain Intensity (PI) than those treated with Placebo during self-paced walks on Day 3 of treatment.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has osteoarthritis of the knee and primary source of pain is knee
  • Females must not be pregnant or nursing and must agree to use throughout the study
  • Is willing to limit alcohol and caffeine intake
  • Is willing to abstain from smoking during study visits
  • Must be able to walk on a treadmill at a pace of at least 1 mile/hour

Exclusion criteria

Exclusion Criteria:

  • Has a medical/arthritic disease that would interfere with evaluation
  • Is unable to take naproxen or Ultracet
  • Has congestive heart failure or angina
  • Has a history of stroke
  • Has a history of uncontrolled high blood pressure
  • Has a history of cancer
  • Regularly uses a walker or cane
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Placebo, Naproxen, Ultracet

    Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

    Drug: Naproxen · Drug: Placebo · Drug: Ultracet

  • Experimental
    Naproxen, Ultracet, Placebo

    Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

    Drug: Naproxen · Drug: Placebo · Drug: Ultracet

  • Experimental
    Ultracet, Placebo, Naproxen

    Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

    Drug: Naproxen · Drug: Placebo · Drug: Ultracet

  • Experimental
    Placebo, Ultracet, Naproxen

    Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

    Drug: Naproxen · Drug: Placebo · Drug: Ultracet

  • Experimental
    Naproxen, Placebo, Ultracet

    Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

    Drug: Naproxen · Drug: Placebo · Drug: Ultracet

  • Experimental
    Ultracet, Naproxen, Placebo

    Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

    Drug: Naproxen · Drug: Placebo · Drug: Ultracet

Interventions

  • Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

  • DrugPlacebo

    Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

  • Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3

    Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes, rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following a single treatment on Day 3, PI was similarly measured over 20 minute self paced walks at 4 and 6 hrs post-dose. The difference between the TWA (0-20 minutes) PI determined at baseline, and the average of the two TWA (0-20 minutes) PI from the self-paced walks on Day 3 is reported as units on a scale.

    Time frame: Baseline and Day 3

Secondary outcomes

  1. Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 1

    Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes, rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following the first treatment on Day 1, PI was similarly measured over 20 minute self-paced walks at 2, 4, and 6 hrs post-dose . The difference between the TWA (0-20 minutes) PI determined at baseline, and the average of the three TWA (0-20 minutes)PI from the self-paced walks on Day 1 is reported as units on a scale.

    Time frame: Baseline and Day 1

  2. Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 1

    Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes,rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following the first treatment on Day 1, PI was similarly measured over a 20 minute high-paced treadmill walk at 5 hrs post-dose. A high-paced walk is the highest pace that can be walked safely for at least 5 minutes that is at a 10-30% higher rate than a self-paced walk. The difference between the TWA (0-20 minutes) PI determined at baseline, and the TWA (0-20 minutes) PI of the high-paced walk on Day 1 is reported as units on a scale.

    Time frame: Baseline and Day 1

  3. Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 3

    Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes, rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following a single treatment on Day 3, PI was similarly measured over a 20 minute high-paced treadmill walk, at 5 hrs post-dose. A high-paced walk is the highest pace that can be walked safely for at least 5 minutes that is at a 10-30% higher rate than a self-paced walk. The difference between the TWA (0-20 minutes) PI determined at baseline, and the TWA (0-20 minutes) PI of the high-paced walk on Day 3 is reported as units on a scale.

    Time frame: Baseline and Day 3

07

Results

Posted Dec 5, 2012

Participant flow

First Patient Entered: 23 June 2008 Last Patient, Last Visit: 20 November 2008 2 sites

Crossover Treatment 1
Participant flow — Crossover Treatment 1
MilestonePlacebo, Naproxen, UltracetNaproxen, Ultracet, PlaceboUltracet, Placebo, NaproxenPlacebo, Ultracet, NaproxenNaproxen, Placebo, UltracetUltracet, Naproxen, Placebo
Started353443
Completed353343
Not completed000100
Withdrew: Adverse event (pain)000100
Break 1 (4-7 Days)
Participant flow — Break 1 (4-7 Days)
MilestonePlacebo, Naproxen, UltracetNaproxen, Ultracet, PlaceboUltracet, Placebo, NaproxenPlacebo, Ultracet, NaproxenNaproxen, Placebo, UltracetUltracet, Naproxen, Placebo
Started353343
Completed343343
Not completed010000
Withdrew: Withdrawal by subject010000
Crossover Treatment 2
Participant flow — Crossover Treatment 2
MilestonePlacebo, Naproxen, UltracetNaproxen, Ultracet, PlaceboUltracet, Placebo, NaproxenPlacebo, Ultracet, NaproxenNaproxen, Placebo, UltracetUltracet, Naproxen, Placebo
Started343343
Completed343343
Not completed000000
Break 2 (4-7 Days)
Participant flow — Break 2 (4-7 Days)
MilestonePlacebo, Naproxen, UltracetNaproxen, Ultracet, PlaceboUltracet, Placebo, NaproxenPlacebo, Ultracet, NaproxenNaproxen, Placebo, UltracetUltracet, Naproxen, Placebo
Started343343
Completed343343
Not completed000000
Crossover Treatment 3
Participant flow — Crossover Treatment 3
MilestonePlacebo, Naproxen, UltracetNaproxen, Ultracet, PlaceboUltracet, Placebo, NaproxenPlacebo, Ultracet, NaproxenNaproxen, Placebo, UltracetUltracet, Naproxen, Placebo
Started343343
Completed343333
Not completed000010
Withdrew: Adverse event000010

Outcome measures

PrimaryChange From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3

Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes, rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following a single treatment on Day 3, PI was similarly measured over 20 minute self paced walks at 4 and 6 hrs post-dose. The difference between the TWA (0-20 minutes) PI determined at baseline, and the average of the two TWA (0-20 minutes) PI from the self-paced walks on Day 3 is reported as units on a scale.

Time frame:
Baseline and Day 3
Reported as:
Least squares mean · units on a scale
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3
units on a scalePlaceboNaproxenUltracet
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3-0.927 (-1.52 to -0.33)-1.54 (-2.12 to -0.96)-1.73 (-2.34 to -1.12)
Statistical analysis
  • Placebo vs Naproxen · ANCOVA · p = 0.089 (1-sided, alpha = 0.05) · Mean difference (final values): -0.611 · 90% CI -1.36 to 0.14Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
  • Placebo vs Ultracet · ANCOVA · p = 0.043 (1-sided, alpha = 0.05) · Mean difference (final values): -0.804 · 90% CI -1.57 to -0.04Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
SecondaryChange From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 1

Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes, rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following the first treatment on Day 1, PI was similarly measured over 20 minute self-paced walks at 2, 4, and 6 hrs post-dose . The difference between the TWA (0-20 minutes) PI determined at baseline, and the average of the three TWA (0-20 minutes)PI from the self-paced walks on Day 1 is reported as units on a scale.

Time frame:
Baseline and Day 1
Reported as:
Least squares mean · units on a scale
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 1
units on a scalePlaceboNaproxenUltracet
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 1-0.438 (-0.98 to 0.11)-0.956 (-1.51 to -0.40)-1.47 (-2.02 to -0.92)
Statistical analysis
  • Placebo vs Naproxen · ANCOVA · p = 0.048 (1-sided, alpha = 0.05) · Mean difference (final values): -0.518 · 90% CI -1.03 to -0.01Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
  • Placebo vs Ultracet · ANCOVA · p = 0.001 (1-sided, alpha = 0.05) · Mean difference (final values): -1.03 · 90% CI -1.54 to -0.53Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
SecondaryChange From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 1

Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes,rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following the first treatment on Day 1, PI was similarly measured over a 20 minute high-paced treadmill walk at 5 hrs post-dose. A high-paced walk is the highest pace that can be walked safely for at least 5 minutes that is at a 10-30% higher rate than a self-paced walk. The difference between the TWA (0-20 minutes) PI determined at baseline, and the TWA (0-20 minutes) PI of the high-paced walk on Day 1 is reported as units on a scale.

Time frame:
Baseline and Day 1
Reported as:
Least squares mean · units on a scale
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 1
units on a scalePlaceboNaproxenUltracet
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 10.150 (-0.52 to 0.82)-0.508 (-1.18 to 0.17)-1.00 (-1.67 to -0.34)
Statistical analysis
  • Placebo vs Naproxen · ANCOVA · p = 0.052 (1-sided, alpha = 0.05) · Mean difference (final values): -0.658 · 90% CI -1.32 to 0.01Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
  • Placebo vs Ultracet · ANCOVA · p = 0.003 (1-sided, alpha = 0.05) · Mean difference (final values): -1.15 · 90% CI -1.81 to -0.49Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
SecondaryChange From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 3

Baseline measurements of participant-specific knee PI were gathered pre-dose on Day 1 from the briskest possible self-pace constant walks on a treadmill over the course of a 20 minute interval. Over this interval PI readings were taken at time points 0,3,6,9,12,15,18 and 20 minutes, rated on an 11-point numeric rating scale (NRS), with 0: No Pain - 10: Worst Pain You Can Imagine. Following a single treatment on Day 3, PI was similarly measured over a 20 minute high-paced treadmill walk, at 5 hrs post-dose. A high-paced walk is the highest pace that can be walked safely for at least 5 minutes that is at a 10-30% higher rate than a self-paced walk. The difference between the TWA (0-20 minutes) PI determined at baseline, and the TWA (0-20 minutes) PI of the high-paced walk on Day 3 is reported as units on a scale.

Time frame:
Baseline and Day 3
Reported as:
Least squares mean · units on a scale
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 3
units on a scalePlaceboNaproxenUltracet
Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 3-0.234 (-0.85 to 0.38)-1.11 (-1.71 to -0.51)-1.30 (-1.93 to -0.67)
Statistical analysis
  • Placebo vs Naproxen · ANCOVA · p = 0.019 (1-sided, alpha = 0.05) · Mean difference (final values): -0.875 · 90% CI -1.56 to -0.19Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk
  • Placebo vs Ultracet · ANCOVA · p = 0.007 (1-sided, alpha = 0.05) · Mean difference (final values): -1.07 · 90% CI -1.77 to -0.37Baseline measurement included as covariate: Time-weighted average pain intensity during pretreatment walk

Adverse events

Collected over Adverse experiences (AEs) were collected from the time the consent is signed through the 14 day follow up period after all treatment periods were completed.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/22 (0%)0/22 (0%)
Naproxen—0/22 (0%)0/22 (0%)
Ultracet—0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
EventPlaceboNaproxenUltracet
GoutMetabolism and nutrition disorders0/220/221/20
SomnolenceNervous system disorders0/220/221/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean59.6 ± 7.92
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female14
Male8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Peeva E, Beals CR, Bolognese JA, Kivitz AJ, Taber L, Harman A, Smugar SS, Moskowitz RW. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis Cartilage. 2010 May;18(5):646-53. doi: 10.1016/j.joca.2009.12.008. Epub 2010 Feb 6. PubMed 20175977 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2008
First posted
Oct 15, 2008
Start
Jun 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Dec 5, 2012
Last update
Nov 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00772967
Responsible party
Sponsor
First posted
Oct 15, 2008
Start date
Jun 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 5, 2012
Last update
Nov 20, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naproxen · Ultracet

Start the discussion